ICMR recommends use of combo; asks to ramp up production

April 6, 2020 0 By FM

ICMR, meanwhile, issued a protocol for the restricted use of the lopinavir/ritonavir combo in patients with COVID-19 infection.

In view of the earlier evidence about the effectiveness of repurposed lopinavir/ritonavir against severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS) coronavirus (CoV), as well as preliminary docking studies conducted by the ICMR, the CDSCO had approved the restricted public health use of lopinavir/ritonavir combination amongst symptomatic COVID-19 patients detected in the country, reports said.

In a related development, the National Pharmaceuticals Pricing Authority (NPPA), Department of Pharmaceuticals directed 3 major manufacturers of HIV drugs lopinavir/ritonavir to maintain adequate stocks of the combination at any point of time and also to ensure sufficient availability to fight against the corona pandemic.